NCT07170046Not yet recruiting
Predictive Value of CEA and ctDNA in Lung Cancer Recurrence
Predictive Value of CEA and ctDNA for Postoperative Recurrence in Patients With High CEA Sensitivity Lung Cancer
Source: ClinicalTrials.gov · Last updated 12 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The study aims to investigate the predictive value of CEA levels for postoperative recurrence in the highly sensitive CEA lung cancer patients and to explore whether the dynamic changes of postoperative CEA and MRD in this population are related.This study was carried out to accurately predict the recurrence time, save the time and cost of changing the intervention strategy, and provide more personalized treatment for patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 7 Sept 2025
- Start date
- 15 Sept 2025
- Primary completion date
- 1 Aug 2027
- Lead sponsor
- Guangdong Provincial People's Hospital
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT07170046
What you commit to
- Study type: Observational
- Planned participants: 100
- From 15 Sept 2025 to the primary completion date, 1 Aug 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with a history of malignant tumors within the past five years
- Patients with secondary lung cancer
Other
- Those without available imaging records
Who the study is looking for
- Preoperative CEA \> 5mg/l
- MRD testing was conducted before the operation
- The primary lesion was resected through surgery
- There should be at least two CEA and MRD follow-up tests within 2 years after the operation
- Postoperative pathology confirmed it as a malignant lung tumor
Age in the registry: 15 years to 100 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.